Prime Medicine, Inc.PRMENASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 56% recommend buying.

Consensus Rating

Buy

9 analysts·Limited coverage

56%

Rating Distribution

Strong Buy

00%

Buy

556%

Hold

444%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 354% higher.

Bear Case

$12.00

+216%

Consensus

$17.25

+354%

Bull Case

$23.00

+505%

Price Range9 analysts

Low

Consensus

High

$12.00

$23.00

Current Target

Current Price

$3.80

Upside to Target

$13.45

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-0.93(8 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+30.31%

EPS—

FY2028

Rev-79.39%

EPS—

FY2029

Rev+85.94%

EPS—

Earnings Surprises

Beat rate:25%(3/12 quarters)

Avg surprise:-7.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

May 7, 2024Jefferies

Prime Medicine assumed with a Buy at Jefferies

Target:$15.00

+177.8%from $5.40

Apr 2, 2024Wedbush

Prime Medicine initiated with a Buy at Wedbush

Target:$12.00

+89.9%from $6.32

Oct 9, 2023BMO Capital

Preclinical-Phase Firm Prime Medicine's Gene Editing Platform Has Potential: Analyst

Target:$19.00

+117.1%from $8.75

Nov 14, 2022Morgan Stanley

Morgan Stanley Initiates Coverage On Prime Medicine with Equal-Weight Rating, Announces Price Target of $23

Target:$23.00

+8.9%from $21.12

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance